US OptionsDetailed Quotes

OMCL241018P45000

Watchlist

3.45
0.000.00%

15min DelayClose Oct 18 16:00 ET

0.00High0.00Low

Omnicell Stock Discussion

Moomoo AI

Feb 23 05:55

Omnicell stock is undervalued, presenting a buying opportunity. The company's future outlook is optimistic with robust cash flows expected to increase share value. However, consider other factors like financial health before investing.

Is Now The Time To Look At Buying Omnicell, Inc. (NASDAQ:OMCL)?

Moomoo AI

Feb 5 08:15

The company's debt situation and EBIT loss of US$31m over the last twelve months raise concerns about its financial health. The balance sheet is considered far from match-fit and the stock is deemed very risky.

Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

Moomoo AI

Dec 25, 2023 05:09

Omnicell's low P/S ratio suggests limited growth. Lackluster future revenue forecasts damages its value. Investors await improved performance as current weak outlook pressures stock price.

Omnicell, Inc.'s (NASDAQ:OMCL) Share Price Is Matching Sentiment Around Its Revenues

Moomoo AI

Dec 6, 2023 05:40

Given the falling EPS and poor performance over the last three years, future earnings performance is being considered critical for shareholders. Potential investors are cautioned to ensure they are investing in a high-quality business amid challenges.

Shareholders in Omnicell (NASDAQ:OMCL) Have Lost 70%, as Stock Drops 3.2% This Past Week

Moomoo AI

Nov 10, 2023 04:40

The sharp cut to revenue forecasts suggests that investors should temper their expectations for Omnicell, Inc. Also, analysts anticipate slower revenue growth than the wider market, which could lead to increased caution among investors.

These Analysts Think Omnicell, Inc.'s (NASDAQ:OMCL) Sales Are Under Threat

Moomoo AI

Nov 1, 2023 14:12

Omnicell's recent financial troubles and its current liabilities make it a risky investment. Investors should bear in mind the firm's debt management and performance when considering its viability.

Here's Why Omnicell (NASDAQ:OMCL) Can Afford Some Debt

Analysts Notebook

Jul 15, 2022 07:38

Columns Top upgrades and downgrades on 7/15: QCOM, DAL, CSCO, DRE and more

Upgrades
• $Allogene Therapeutics (ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX (CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp (CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $TechnipFMC (FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern (NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...

No comment yet